A Clinical Study of Vonoprazan Fumarate Tablets for the Treatment of Non-erosive Reflux Disease

Xiaoyun LI; Jiahao LIU; Weiwei ZHANG; Rongjian CAO; Yan LIU; Zhenguang QI

doi:10.12259/j.issn.2095-610X.S20240421

Volume 45 Issue 4

Apr. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(4): 146-151

Xiaoyun LI, Jiahao LIU, Weiwei ZHANG, Rongjian CAO, Yan LIU, Zhenguang QI. A Clinical Study of Vonoprazan Fumarate Tablets for the Treatment of Non-erosive Reflux Disease[J]. Journal of Kunming Medical University, 2024, 45(4): 146-151. doi: 10.12259/j.issn.2095-610X.S20240421

Citation:

Xiaoyun LI, Jiahao LIU, Weiwei ZHANG, Rongjian CAO, Yan LIU, Zhenguang QI. A Clinical Study of Vonoprazan Fumarate Tablets for the Treatment of Non-erosive Reflux Disease[J]. Journal of Kunming Medical University, 2024, 45(4): 146-151. doi: 10.12259/j.issn.2095-610X.S20240421

Citation:

PDF( 589 KB)

A Clinical Study of Vonoprazan Fumarate Tablets for the Treatment of Non-erosive Reflux Disease

doi: 10.12259/j.issn.2095-610X.S20240421

1.
Dept. of Education，The 8th People’s Hospital of Qingdao，Qingdao Shandong 266041
2.
Minimally Invasive Interventional Treatment Center
3.
Dept. of Gastroenterology，East Branch，Qingdao Municipal Hospital ，Qingdao Shandong 266071
4.
Dept. of Infectious Diseases，Yinan County People's Hospital，Yinan Shandong 276000
5.
Dept. of Gastroenterology，The Affiliated Hospital of Qingdao University，Qingdao Shandong 266003
6.
Dept. of Gastroenterology，The 8th People’s Hospital of Qingdao，Qingdao Shandong 266041，China

Received Date: 2022-11-23
Available Online: 2023-12-22
Publish Date: 2024-04-29

Abstract

Abstract

Objective To study the efficacy and adverse reactions of vonoprazan fumarate tablets and esomeprazole magnesium enteric-coated tablets in the treatment of non-erosive reflux disease（NERD）. Methods A total of 124 patients with NERD were selected and divided into treatment group（62 cases） and control group（62 cases） by random number table method. Treatment group received vohoprazan fumarate tablet, while control group received esomeprazole magnesium enteric-coated tablet, and the course of treatment was 4 weeks. HP was eradicated in helicobacter pylori（HP）-positive patients. The clinical efficacy, reflux disease questionnaire（RDQ ）score, pittsburgh sleep quality index score, changes of esophageal pH before and after treatment、HP eradication rate and incidence of adverse reactions were compared between the two groups. Results The treatment group showed a higher overall effectiveness compared to the control group（P < 0.05）. After treatment, the RDQ scores in the treatment group were lower than those in the control group（P < 0.05）. Similarly, the PSQI scores in the treatment group were lower than those in the control group（P < 0.05）. Additionally, the treatment group exhibited fewer reflux episodes with pH < 4, reflux episodes lasting > 5 minutes, and a lower total time with pH < 4 compared to the control group（P < 0.05）. The eradication rate of HP in the treatment group was higher than that in the control group（P < 0.05）. There was no significant difference in the overall rate of adverse reactions between the treatment group and the control group（P > 0.05）. Conclusion In the treatment of non-erosive reflux disease, compared to esomeprazole magnesium enteric-coated tablets, vonoprazan fumarate tablets show significant efficacy, improve sleep quality, provide stronger acid suppression, increase the eradication rate of Helicobacter pylori（HP）, and do not increase adverse reactions.
- Vonoprazan fumarate tablets,
- Esomeprazole magnesium enteric-coated tablets,
- Non-erosive reflux disease

FullText(HTML)

References(24)

References

[1]	Savarino V,Antonioli L,Fornai M,et al. An update of pharmacology,efficacy,and safety of vonoprazan in acid-related disorders[J]. Expert Rev Gastroenterol Hepatol,2022,16(5):401-410. doi: 10.1080/17474124.2021.1984878
[2]	沈芸,陶雯佳,杨勤. 新型钾离子竞争性酸阻滞剂在治疗酸相关疾病中的研究进展[J]. 中国中西医结合消化杂志,2020,28(10):811-814.
[3]	中华医学会消化病学分会. 2020年中国胃食管反流病专家共识意见[J]. 中华消化杂志,2020,40(10):649-663.
[4]	崔亚,姜礼双,卜平. 反流性食管炎与非糜烂性胃食管反流病临床特征比较[J]. 中国医师杂志,2018,20(8):1151-1154.
[5]	杜秀云,赛米·赛麦提,赵新胜,等. P物质和降钙素基因相关肽及炎症因子在非糜烂性食管炎发生中的作用研究[J]. 中华胃食管反流病电子杂志,2020,7(3):158-163.
[6]	中华中医药学会脾胃病分会. 胃食管反流病中医诊疗专家共识意见(2017)[J]. 中国中西医结合消化杂志,2017,25(5):321-326.
[7]	Kim M,Yu H Y,Ju H,et al. Induction of detrusor underactivity by extensive vascular endothelial damages of iliac arteries in a rat model and its pathophysiology in the genetic levels[J]. Sci Rep,2019,9(1):16328. doi: 10.1038/s41598-019-52811-4
[8]	Maret-Ouda J,Markar S R,Lagergren J. Gastroesophageal reflux disease: A review[J]. JAMA,2020,324(24):2536-2547. doi: 10.1001/jama.2020.21360
[9]	Lim K G,Morgenthaler T I,Katzka D A. Sleep and nocturnal gastroesophageal reflux: An update[J]. Chest,2018,154(4):963-971. doi: 10.1016/j.chest.2018.05.030
[10]	Park Chan Hyuk. Treatment of non-erosive reflux disease and dynamics of the esophageal microbiome: A prospective multic-enter study[J]. Scientific Reports,2020,10(1):1025. doi: 10.1038/s41598-020-57894-y
[11]	Echizen H. The first-in-class potassium-competitive acid blocker,Vonoprazan Fumarate: Pharmacokinetic and pharmacodynamic considerations[J]. Clin Pharmacokinet,2016,55(4):409-418. doi: 10.1007/s40262-015-0326-7
[12]	Okanobu H,Kohno T,Mouri R,et al. Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: A randomized pilot study[J]. Esophagus,2021,18(3):669-675. doi: 10.1007/s10388-020-00798-7
[13]	Cheng Y,Liu J,Tan X,et al. Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: A systematic review and meta-analysis[J]. Dig Dis Sci,2021,66(1):19-28. doi: 10.1007/s10620-020-06141-5
[14]	Akiyama J,Hosaka H,Kuribayashi S,et al. Efficacy of vonoprazan,a novel potassium-competitive acid blocker,in patients with proton pump inhibitor-refractory acid reflux[J]. Digestion,2020,101(2):174-183. doi: 10.1159/000497775
[15]	Takenouchi N,Hoshino S,Hoshikawa Y,et al. Risk of hemorrhage and stricture significantly increases in elderly patients with proton pump inhibitor (PPI)-resistant reflux esophagitis[J]. Esophagus,2020,17(1):87-91. doi: 10.1007/s10388-019-00702-y
[16]	黄博,崔德军,赵寻,等. 伏诺拉生治疗难治性反流性食管炎的临床疗效及安全性[J]. 临床合理用药杂志,2021,14(25):18-20.
[17]	Takeuchi T,Furuta T,Fujiwara Y,et al. Randomised trial of acid inhibition by vonoprazan 10/20mg once daily vs rabeprazole 10/20mg twice daily in healthy Japanese volunteers (SAMURAI pH study)[J]. Aliment Pharmacol Ther,2020,51(5):534-543. doi: 10.1111/apt.15641
[18]	赵莹,赵晶. 伊托必利联合富马酸伏诺拉生片治疗胃食管反流病的疗效及对患者CGRP、5-HT水平变化的影响[J]. 中国中西医结合消化杂志,2022,30(1):16-20.
[19]	张泽丹,黄敏,谭平. 不同亚型胃食管反流病睡眠障碍状况及治疗对睡眠障碍的影响[J]. 中华保健医学杂志,2021,23(2):120-122.
[20]	里提甫江·买买提艾力,买买提·依斯热依力,阿巴伯克力·乌斯曼,等. 焦虑、抑郁及睡眠障碍与胃食管反流病的相关研究[J]. 中华胃食管反流病电子杂志,2020,7(4):202-206.
[21]	Rokkas T,Gisbert JP,Malfertheiner P,et al. Comparative effectiveness of multiple different first-line treatment regimens for helicobacter pylori infection: A network meta-analysis[J]. Gastroenterology,2021,161(2):495-507. doi: 10.1053/j.gastro.2021.04.012
[22]	Ford A C,Yuan Y,Forman D,et al. Helicobacter pylori eradication for the prevention of gastric neoplasia[J]. Cohrane Database of Systematic Reviews,2020,7(7):CD005583.
[23]	Kato M,Ota H,Okuda M,et al. Guidelines for the manage-ment of elicobacter pylori infection in Japan: 2016 revised edition[J]. Helicobacter,2019,24(4):e12597. doi: 10.1111/hel.12597
[24]	Dong S Q,Singh T P,Wei X,et al. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for helicobacter pylori eradication therapy: Is superiority an illusion?[J]. Helicobacter,2017,22(6):e12438. doi: 10.1111/hel.12438

Relative Articles(20)

Relative Articles

[1]	Liping DUAN, Xiaoxue CHEN, Zhi YANG, Yinshuang WU, Junyu LIU, Di JIN. Preparation and in Vitro-in Vivo Evaluation of Aspirin Enteric-coated Tablets. Journal of Kunming Medical University, 2024, 45(6): 69-74. doi: 10.12259/j.issn.2095-610X.S20240609
[2]	Xing LIU, Chunhong YU, Weixian LI, Bing OUYANG, Lingjun SHEN. A Randomized Controlled Study on the Treatment of Multidrugresistant Tuberculosis with a Regimen Containing Bedaquiline Fumarate Tablets. Journal of Kunming Medical University, 2023, 44(12): 150-158. doi: 10.12259/j.issn.2095-610X.S20231224
[3]	Jin-hong LI, Hong WANG. Efficacy and Safety of Valsartan Amlodipine Tablets Combined with Alpha-lipoic Acid in the Treatment of Elderly Patients with Type 2 Diabetic Nephropathy Complicated with Hypertension. Journal of Kunming Medical University, 2021, 42(4): 53-56. doi: 10.12259/j.issn.2095-610X.S20210410
[4]	Li LIU, Jun-yi LI, Chun-yun LIU, Ying-rong DU, Jian-peng GAO, Hui-ming LI, Wei-kun LI, Yan-wei QI, Hui WANG. Effect of Tenofovir Combined with Ganshuang Granule on Hemodynamics of Portal Vein System in Hepatitis B Liver Cirrhosis. Journal of Kunming Medical University, 2021, 42(11): 134-139. doi: 10.12259/j.issn.2095-610X.S20211125
[5]	Yang Han , An Hong Mei , Deng Ji Hong , Zhang Wen , Liu Shuang Yue, Xie Ming Zhu , Chu Li Ping . . Journal of Kunming Medical University, 2020, 41(07): 140-143.
[6]	Ji Shu Yu , Zhong Hua , Li Lei , Feng Shi Ting . . Journal of Kunming Medical University, 2019, 40(07): 47-50.
[7]	Zhang Xue Qin , Xu Xiao Lin . Clinical Effect of Lansoprazole on Patients with Gastroesophageal Reflux and the Esophageal Dynamics. Journal of Kunming Medical University, 2017, 38(04): 76-79.
[8]	Ma Yan , Niu Yan , Wu Hai Ying , Lv Cao , Bai Zhong . Treatment Efficacy of Pantoprazole and Domperidone on Larygopharyngeal Reflux Disease. Journal of Kunming Medical University, 2017, 38(04): 98-100.
[9]	Tian Wei . Liraglutide Improves The Symptoms of Non-alcoholic Fatty Liver Disease by Regulating Fatty Acid β-oxidation. Journal of Kunming Medical University,
[10]	Zhao Li Dong . Clincal Effect of Different Doses of Esomeprazole in Treatment of Acute Nonvariceal Upper Gastrointestinal Bleeding. Journal of Kunming Medical University,
[11]	Wang Xiu Hua . . Journal of Kunming Medical University,
[12]	Liu Yan . . Journal of Kunming Medical University,
[13]	Li Yan Yuan . . Journal of Kunming Medical University,
[14]	Wang Ji Cai . . Journal of Kunming Medical University,
[15]	Chen Yong Sheng . . Journal of Kunming Medical University,
[16]	Han Ya Qiong . . Journal of Kunming Medical University,
[17]	Lu Chao Xue . . Journal of Kunming Medical University,
[18]	Huang Qin . . Journal of Kunming Medical University,
[19]	Min Wan Cang . . Journal of Kunming Medical University,
[20]	. Curative Effects of Integrating Pantoprazole and Mosapride on Gastroesophageal Reflux Disease after Esophagectomy. Journal of Kunming Medical University,